drugset / Trial / NCT03792750

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

NCT03792750

Phase 1/2 Completed 12 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.

Timeline

Start
2018-12-31
Primary completion
2020-12-18
Completion
2020-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject LINRODOSTAT Small molecule
Background Nivolumab Monoclonal antibody